HLH

What HLH Means in Everyday Medical Language

Hemophagocytic lymphohistiocytosis, often called HLH, is a rare but serious condition where the immune system becomes overactive. Normally, immune cells called lymphocytes and histiocytes help protect the body from infections. In HLH, these cells multiply too much and start attacking the body’s own tissues, including organs like the liver, spleen, and skin. This causes inflammation and damage, leading to symptoms such as fever, enlarged organs, rash, and problems with blood cells. HLH can be inherited, meaning it runs in families due to genetic changes, or it can develop later in life triggered by infections, immune system problems, or cancer.

Why HLH Can Matter in Cancer Care

HLH is important in cancer care because it can be triggered by cancers, especially blood cancers like lymphomas and leukemias. It may also occur as a severe immune reaction during some cancer treatments. The immune system’s overactivity in HLH can cause serious harm if not treated promptly. Medicines like emapalumab (brand name Gamifant) have been developed to help calm the immune system by blocking a protein called interferon gamma, which plays a key role in the immune overreaction seen in HLH. While emapalumab is not a cancer treatment itself, it is used to manage HLH when it occurs alongside cancer or other conditions.

What Patients Might See, Feel, Read, or Be Told About HLH

Patients or caregivers might hear the term HLH in medical reports, treatment plans, or discussions about symptoms like persistent fever, enlarged liver or spleen, rash, or unusual blood test results. Doctors may explain that HLH is a rare immune disorder that requires urgent treatment. If standard treatments don’t work, medicines like emapalumab may be offered. Side effects of such treatments can include infections, fever, or reactions during medicine infusion. Because HLH symptoms can resemble severe infections or sepsis, it can sometimes be confusing to understand the diagnosis.

Where the Term HLH Might Appear

HLH may be mentioned in medical records, pathology reports, treatment plans, or drug information pages. You might also see it in clinical trial descriptions or discussions about immune system complications related to cancer or infections. The medicine emapalumab, also known as Gamifant or emapalumab-lzsg, is approved for treating HLH that does not respond to other therapies. Seeing different names for the same medicine is common and does not indicate different treatments.

Common Confusions and How to Understand HLH and Its Treatments

HLH is sometimes confused with infections or sepsis because symptoms overlap. It is also not a cancer itself but can be related to cancer or its treatments. Medicines like emapalumab are not chemotherapy drugs; instead, they work by blocking a protein called interferon gamma to reduce harmful immune activity. If you see terms like HLH, hemophagocytic lymphohistiocytosis, Gamifant, or emapalumab in your records, it’s helpful to ask your care team how they relate to your health situation.

Safety and Next Steps

This information is meant to help you understand HLH and related treatments but does not replace medical advice. HLH is a complex and serious condition that requires expert care. If you or a loved one has HLH mentioned in medical notes or treatment plans, the best next step is to talk with your healthcare team. They can explain what HLH means for your specific case, what treatments are recommended, and what to watch for during care.